Cargando…

Anticipated effects of burosumab treatment on long-term clinical sequelae in XLH: expert perspectives

X-linked hypophosphatemia (XLH) is a rare, progressive, genetic disease with multisystem impact that typically begins to manifest in early childhood. Two treatment options exist: oral phosphate in combination with active vitamin D (“conventional therapy”) and a fully human monoclonal anti-FGF23 anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seefried, Lothar, Duplan, Martin Biosse, Briot, Karine, Collins, Michael T., Evans, Rachel, Florenzano, Pablo, Hawkins, Neil, Javaid, Muhammad Kassim, Lachmann, Robin, Ward, Leanne M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10400326/ https://www.ncbi.nlm.nih.gov/pubmed/37547321 http://dx.doi.org/10.3389/fendo.2023.1211426

Ejemplares similares

Benefit of burosumab in adults with X-linked hypophosphataemia (XLH) is maintained with long-term treatment
por: Kamenicky, Peter, et al.
Publicado: (2023)

XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH)
por: Seefried, Lothar, et al.
Publicado: (2023)

SUN-523 XLH Outcome Data from One Centre Experience with Burosumab
por: Cheung, Moira, et al.
Publicado: (2019)

SUN-356 Burosumab Resulted in Greater Clinical Improvements Compared with Higher-dose Conventional Therapy in Children with X-linked Hypophosphatemia (XLH)
por: Imel, Erik A, et al.
Publicado: (2020)

OR13-2 Burosumab Resulted in Greater Improvement in Rickets Than Conventional Therapy in Children with X-Linked Hypophosphatemia (XLH)
por: Imel, Erik, et al.
Publicado: (2019)

Burosumab and Dental Abscesses in Children With X‐Linked Hypophosphatemia
por: Gadion, Margaux, et al.
Publicado: (2022)

Clinical Evidence for the Benefits of Burosumab Therapy for X-Linked Hypophosphatemia (XLH) and Other Conditions in Adults and Children
por: Schindeler, Aaron, et al.
Publicado: (2020)

Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations
por: Padidela, Raja, et al.
Publicado: (2020)

Body composition and cardiometabolic health of pediatric patients with X-linked hypophosphatemia (XLH) under burosumab therapy
por: Brener, Avivit, et al.
Publicado: (2021)

Dental health of pediatric patients with X-linked hypophosphatemia (XLH) after three years of burosumab therapy
por: Brener, Rafi, et al.
Publicado: (2022)

SUN-524 Burosumab Initiation In A UK XLH Cohort: Real-World Use Resonates With Research Evidence
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

OR29-01 Long-Term Safety in Adults with X-Linked Hypophosphatemia (XLH) Treated with Burosumab, a Fully Human Monoclonal Antibody Against FGF23: Final Results of a Phase 3 Trial
por: Perwad, Farzana, et al.
Publicado: (2020)

Novel use of burosumab in refractory iron-induced FGF23-mediated hypophosphataemic osteomalacia
por: Amarnani, Raj, et al.
Publicado: (2020)

Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report
por: Takashi, Yuichi, et al.
Publicado: (2022)

Burosumab for X-linked hypophosphataemia
Publicado: (2021)

The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical data
por: Ariceta, Gema, et al.
Publicado: (2023)

Burosumab for the Treatment of Tumor‐Induced Osteomalacia
por: Jan de Beur, Suzanne M, et al.
Publicado: (2021)

X-linked Hypophosphatemia (XLH) Mimicking Rheumatic Disease
por: Takase, Ryosuke, et al.
Publicado: (2020)

The ankle in XLH: Reduced motion, power and quality of life
por: Akta, Celine, et al.
Publicado: (2023)

Therapeutic management of hypophosphatemic rickets from infancy to adulthood
por: Linglart, Agnès, et al.
Publicado: (2014)

Phenotypes of a family with XLH with a novel PHEX mutation
por: Yamamoto, Akiko, et al.
Publicado: (2020)

SUN-363 Hypophosphatemia Gene Panel Sponsored Program: A High Yield Of Molecular Diagnoses from Clinically Confirmed XLH and Suspected XLH/ Genetic Hypophosphatemia
por: Miller, Nicole, et al.
Publicado: (2020)

Post-authorisation safety study of burosumab use in paediatric, adolescent and adult patients with X-linked hypophosphataemia: rationale and description
por: Brandi, Maria Luisa, et al.
Publicado: (2022)

Multiple early factors anticipate post-acute COVID-19 sequelae
por: Su, Yapeng, et al.
Publicado: (2022)

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension
por: Briot, Karine, et al.
Publicado: (2021)

Young XLH Patients-Reported Experience with a Supportive Care Program
por: Rothenbuhler, Anya, et al.
Publicado: (2023)

Evolving treatment landscape: 18 years of managing melanoma in a single patient
por: Biosse-Duplan, Garance, et al.
Publicado: (2021)

Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia
por: Ward, Leanne M, et al.
Publicado: (2022)

SUN-525 Burosumab Experience In A UK Adolescent Population
por: Dharmaraj, Poonam, et al.
Publicado: (2019)

Long-term use of burosumab for the treatment of tumor-induced osteomalacia
por: Crotti, C., et al.
Publicado: (2022)

Clinical identification and endodontic management of furcation canals: a case series
por: Kuoch, Pierre, et al.
Publicado: (2023)

Wnt pathway inhibitors are upregulated in XLH dental pulp cells in response to odontogenic differentiation
por: Guirado, Elizabeth, et al.
Publicado: (2023)

OR13-2 Characterizing the Impact of Burosumab on Bone Health in Children with X-Linked Hypophosphatemia: Results from Year 1 of the Disease Monitoring Program
por: Carpenter, Thomas, et al.
Publicado: (2022)

Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Reply to: Burosumab for Tumor‐Induced Osteomalacia: not Enough of a Good Thing
por: Jan de Beur, Suzanne M., et al.
Publicado: (2021)

Tumour-induced osteomalacia: 18 months of 2-weekly burosumab treatment
por: Aliberti, L, et al.
Publicado: (2023)

Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level
por: Imel, Erik A, et al.
Publicado: (2023)

THU466 XLH During Pregnancy: A Closer Look Based On Real-World Experience
por: Ali, Dalal S, et al.
Publicado: (2023)

Anticiper la nouvelle ISO 19011: des experts vous accompagnent !
por: Association Française de Normalisation. Paris
Publicado: (2010)

Correction to: Burosumab in X-linked hypophosphatemia: a profile of its use in the USA
por: Lyseng-Williamson, Katherine A.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tgkcc2n6093rgub0mrpvrc48au